Stroke risk may be more than 3-fold higher among patients with chronic kidney disease stage 5D (CKD-5D) compared to the general population, with the highest stroke rates noted among those 85 years and older. Atrial fibrillation (AF), a strong risk factor for stroke, is the most common arrhythmia and affects >7% of the population with CKD-5D. Warfarin use is widely acknowledged as an important intervention for stroke prevention with nonvalvular AF in the general population. However, use of oral anticoagulants for stroke prevention in patients with CKD-5D and nonvalvular AF continues to be debated by the nephrology community. In this National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) controversies report, we discuss the existing observational studies that examine warfarin use and associated stroke and bleeding risks in adults with CKD-5D and AF. Non-vitamin K-dependent oral anticoagulants and their potential use for stroke prevention in patients with CKD-5D and nonvalvular AF are also discussed. Data from randomized clinical trials are urgently needed to determine the benefits and risks of oral anticoagulant use for stroke prevention in the setting of AF among patients with CKD-5D.
Keywords: Atrial fibrillation (AF); CKD stage 5D; Kidney Disease Outcomes Quality Initiative (KDOQI); bleeding; chronic kidney disease (CKD); dialysis; dialysis-dependent CKD; end-stage renal disease (ESRD); hemodialysis; hemorrhage; kidney failure; nonvalvular AF; oral anticoagulants; peritoneal dialysis; stroke; transient ischemic attack (TIA); warfarin.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.